https://www.onclive.com/view/esr1-mutations-steer-the-oral-serd-story-in-breast-cancer-with-sara-nunnery-md-msci-and-minhtri-nguyen-md2026-07-07T17:00:00Z2026-07-07T17:00:00Z https://www.onclive.com/view/dana-farber-investigators-report-promising-results-from-phase-2-study-of-targeted-therapy-for-rare-bile-duct-cancer2026-07-07T16:00:00Z2026-07-07T16:00:00Z https://www.onclive.com/view/ai-finds-new-applications-in-oncologic-surgery-drug-and-biomarker-screening-and-clinical-trial-design2026-07-07T14:05:04.406Z2026-07-07T14:05:04.406Z https://www.onclive.com/view/dr-spencer-on-early-efficacy-data-for-in-vivo-car-t-cell-therapy-in-r-r-myeloma2026-07-07T14:00:00Z2026-07-07T14:00:00Z https://www.onclive.com/view/adagrasib-plus-cetuximab-misses-os-pfs-end-points-in-pretreated-kras-g12c-mutated-crc2026-07-07T13:00:00Z2026-07-07T13:00:00Z https://www.onclive.com/view/hr-positive-her2-negative-metastatic-breast-cancer-molecular-testing-and-targeted-therapy-selection-after-disease-progression2026-07-07T12:15:00Z2026-07-07T12:15:00Z https://www.onclive.com/view/adcs-in-cns-disease-and-managing-patients-with-multiple-biomarkers2026-07-07T12:10:00Z2026-07-07T12:10:00Z https://www.onclive.com/view/the-case-for-first-line-therapy-and-understanding-trop2-as-a-target2026-07-07T12:05:00Z2026-07-07T12:05:00Z https://www.onclive.com/view/early-treatment-access-and-palliative-care-integration-for-patients-with-es-sclc2026-06-23T12:05:00.000Z2026-07-07T12:05:00Z https://www.onclive.com/view/os-benefit-patient-communication-and-frontline-risk-in-dlbcl2026-07-07T12:05:00Z2026-07-07T12:05:00Z https://www.onclive.com/view/safety-tolerability-and-mechanism-of-duvelisib2026-07-07T12:05:00Z2026-07-07T12:05:00Z https://www.onclive.com/view/phase-1-data-highlight-potential-utility-for-in-vivo-car-t-cell-therapy-in-r-r-myeloma2026-07-07T12:00:00Z2026-07-07T12:00:00Z https://www.onclive.com/view/choosing-between-two-frontline-regimens-in-dlbcl2026-07-07T12:00:00Z2026-07-07T12:00:00Z https://www.onclive.com/view/clinical-scenario-cns-only-progression-on-osimertinib-in-egfr-mutated-nsclc2026-07-07T12:00:00Z2026-07-07T12:00:00Z https://www.onclive.com/view/nccn-guideline-updates-and-choosing-a-first-line-adc2026-07-07T12:00:00Z2026-07-07T12:00:00Z https://www.onclive.com/view/limitations-of-phase-1b-data-and-biomarker-development-in-es-sclc2026-06-23T12:05:00.000Z2026-07-07T12:00:00Z https://www.onclive.com/view/primo-trial-design-and-efficacy-in-relapsed-refractory-ptcl2026-07-07T12:00:00Z2026-07-07T12:00:00Z https://www.onclive.com/view/hr-positive-her2-negative-metastatic-breast-cancer-sequencing-strategies-after-cdk4-6-inhibitor-progression2026-07-07T12:00:00Z2026-07-07T12:00:00Z https://www.onclive.com/view/dr-spencer-on-differentiating-factors-for-in-vivo-car-t-cell-therapy-in-myeloma2026-07-06T21:28:14.161Z2026-07-06T21:28:14.161Z https://www.onclive.com/view/fda-issues-crl-to-orviglance-for-liver-metastasis-imaging-in-patients-with-severe-kidney-impairment2026-07-06T20:40:26.861Z2026-07-06T20:40:26.861Z https://www.onclive.com/view/epcoritamab-plus-lenalidomide-rituximab-win-eu-approval-for-r-r-follicular-lymphoma2026-07-06T20:24:32.221Z2026-07-06T20:24:32.221Z https://www.onclive.com/view/dr-bose-on-the-rationale-for-evaluating-sapablursen-in-polycythemia-vera2026-07-06T19:27:13.448Z2026-07-06T19:27:13.448Z https://www.onclive.com/view/dr-rao-on-the-prognostic-value-of-post-surgical-ctdna-status-in-early-tnbc2026-07-06T17:00:00Z2026-07-06T17:00:00Z https://www.onclive.com/view/roswell-park-documents-remarkably-high-success-rate-for-allogeneic-stem-cell-transplants2026-07-06T16:00:00Z2026-07-06T16:00:00Z https://www.onclive.com/view/savolitinib-gains-nmpa-approval-for-met-amplified-gastric-and-gej-adenocarcinoma2026-07-06T15:00:14.010Z2026-07-06T15:00:14.010Z https://www.onclive.com/view/health-canada-green-lights-ropeginterferon-alfa-2b-for-polycythemia-vera2026-07-06T14:42:25.793Z2026-07-06T14:42:25.793Z https://www.onclive.com/view/divarasib-outperforms-first-generation-kras-g12c-inhibitors-in-phase-iii-nsclc-t2026-07-06T13:44:45.106Z2026-07-06T13:44:45.106Z https://www.onclive.com/view/tp53-status-and-time-toxicity-shape-sequencing-decisions-in-egfr-mutated-nsclc2026-07-06T13:00:00Z2026-07-06T13:00:00Z https://www.onclive.com/view/introducing-radioligand-equivalent-terminology2026-07-06T12:05:00Z2026-07-06T12:05:00Z https://www.onclive.com/view/high-risk-disease-management-and-biomarker-guided-decisions2026-07-06T12:05:00Z2026-07-06T12:05:00Z https://www.onclive.com/view/colorectal-cancer-observational-data-and-risk-stratification2026-07-06T12:05:00Z2026-07-06T12:05:00Z https://www.onclive.com/view/her2-positive-early-breast-cancer-balancing-pcr-and-idfs-in-treatment-selection2026-07-06T12:05:00Z2026-07-06T12:05:00Z https://www.onclive.com/view/advantages-of-the-505-b-2-pathway-and-bridging-evidence-requirements2026-07-06T12:00:00Z2026-07-06T12:00:00Z https://www.onclive.com/view/sequoia-long-term-follow-up-and-zanubrutinib-monotherapy-data2026-07-06T12:00:00Z2026-07-06T12:00:00Z https://www.onclive.com/view/rusfertide-maintains-long-term-thromboembolism-control-in-phlebotomy-dependent-polycythemia-vera2026-07-06T12:00:00Z2026-07-06T12:00:00Z https://www.onclive.com/view/her2-positive-early-breast-cancer-reviewing-destiny-breast05-and-residual-disease-management2026-07-06T12:00:00Z2026-07-06T12:00:00Z https://www.onclive.com/view/breast-cancer-ctdna-surveillance-landscape2026-07-06T12:00:00Z2026-07-06T12:00:00Z https://www.onclive.com/view/five-under-5-top-oncology-videos-for-the-week-of-6-282026-07-05T10:00:00Z2026-07-05T10:00:00Z https://www.onclive.com/view/the-oncfive-top-oncology-articles-for-the-week-of-6-282026-07-04T19:21:00Z2026-07-04T19:21:00Z https://www.onclive.com/view/divesiran-reduces-phlebotomy-burden-and-improves-iron-stores-in-polycythemia-vera2026-07-04T10:00:00Z2026-07-04T10:00:00Z https://www.onclive.com/view/study-identifies-rna-surveillance-defect-that-fuels-melanoma-through-endogenous-retroviral-rna2026-07-03T15:00:00Z2026-07-03T15:00:00Z https://www.onclive.com/view/dr-grommes-on-treatment-approaches-in-r-r-pcnsl2026-07-03T14:00:00Z2026-07-03T14:00:00Z https://www.onclive.com/view/belantamab-mafodotin-yields-sustained-mrd-negativity-in-r-r-myeloma2026-07-03T13:00:00Z2026-07-03T13:00:00Z https://www.onclive.com/view/managing-long-term-toxicities-and-emerging-therapies-in-alk-positive-nsclc2026-07-03T12:05:00Z2026-07-03T12:05:00Z https://www.onclive.com/view/luspatercept-sustains-transfusion-independence-favorable-os-trend-esa-naive-lower-risk-mds2026-07-03T12:00:00Z2026-07-03T12:00:00Z https://www.onclive.com/view/unmet-needs-in-desmoid-tumor-treatment-and-special-population-considerations2026-07-03T12:00:00Z2026-07-03T12:00:00Z https://www.onclive.com/view/interpreting-long-term-outcomes-from-the-crown-trial2026-07-03T12:00:00Z2026-07-03T12:00:00Z https://www.onclive.com/view/taking-science-from-bench-to-bedside-to-the-block-introducing-dr-robert-a-winn2026-07-02T15:00:00Z2026-07-02T15:00:00Z https://www.onclive.com/view/dr-meyer-on-the-fda-approval-of-orca-t-for-hsct-in-hematologic-malignancies2026-07-02T14:00:00Z2026-07-02T14:00:00Z https://www.onclive.com/view/namodenoson-meets-safety-end-point-in-pdac-shows-durable-survival-outcomes-pretreated-subgroup2026-07-02T13:00:18.444Z2026-07-02T13:00:18.444Z https://www.onclive.com/view/scientific-rationale-for-combination-therapy-in-patients-with-gist-and-peak-phase-3-data2026-06-18T12:05:00.000Z2026-07-02T12:05:00Z https://www.onclive.com/view/overall-survival-and-early-trial-termination2026-07-02T12:05:00Z2026-07-02T12:05:00Z https://www.onclive.com/view/june-s-gi-rewind-crc-gastric-cancer-see-several-firsts-with-fda-review-of-adjuvant-io-global-approval-of-braf-targeted-and-car-t-cell-therapies2026-07-02T12:00:11.456Z2026-07-02T12:00:11.456Z https://www.onclive.com/view/progression-free-survival-outcomes2026-07-02T12:00:00Z2026-07-02T12:00:00Z https://www.onclive.com/view/community-practice-knowledge-gaps-and-geographic-variation2026-06-18T12:05:00.000Z2026-07-02T12:00:00Z https://www.onclive.com/view/fda-approval-positions-belzutifan-plus-pembrolizumab-as-a-new-adjuvant-standard-in-ccrcc2026-07-01T19:28:30.889Z2026-07-01T19:28:30.889Z https://www.onclive.com/view/surgeons-medical-oncologists-and-radiation-oncologists-debate-current-thresholds-for-systemic-therapy-in-egfr-mutated-nsclc2026-07-01T19:03:30.451Z2026-07-01T19:03:30.451Z https://www.onclive.com/view/zanubrutinib-plus-r-bap-elicits-high-response-rates-in-treatment-naive-mantle-cell-lymphoma2026-07-01T18:02:09.719Z2026-07-01T18:02:09.719Z https://www.onclive.com/view/patient-reported-outcomes-and-toxicity-assessment2026-07-01T17:30:00Z2026-07-01T17:30:00Z https://www.onclive.com/view/comparing-intensification-strategies-and-toxicity-profiles2026-07-01T17:25:00Z2026-07-01T17:25:00Z https://www.onclive.com/view/serena-6-controversies-push-the-breast-cancer-field-to-consider-the-future-role-of-ctdna-guided-treatment-decisions2026-07-01T17:00:00Z2026-07-01T17:00:00Z https://www.onclive.com/view/going-from-the-lab-into-the-fire-to-study-cancer-risk-in-wildland-firefighters2026-07-01T16:00:00Z2026-07-01T16:00:00Z https://www.onclive.com/view/fda-grants-breakthrough-device-designation-to-merlin-cp-gep-for-early-stage-mela2026-07-01T13:29:34.626Z2026-07-01T13:29:34.626Z https://www.onclive.com/view/dr-randall-on-strengths-vs-limitations-of-a-prospective-study-of-ctdna-in-osteosarcoma-mrd-surveillance2026-07-01T13:21:32.471Z2026-07-01T13:21:32.471Z https://www.onclive.com/view/sync-t-sv-102-employs-novel-mechanism-to-target-immunologically-cold-tumors-in-advanced-metastatic-prostate-cancer2026-07-01T13:00:00Z2026-07-01T13:00:00Z https://www.onclive.com/view/the-treatment-landscape-what-failed-what-works-and-how-to-sequence-it2026-07-01T12:15:00Z2026-07-01T12:15:00Z https://www.onclive.com/view/risk-stratification-and-patient-selection2026-07-01T12:05:00Z2026-07-01T12:05:00Z https://www.onclive.com/view/distinguishing-tumor-from-post-surgical-changes-in-patients-with-idh-mutant-glioma2026-07-01T12:05:00Z2026-07-01T12:05:00Z https://www.onclive.com/view/preserving-performance-status-and-the-impact-of-nalirifox-s-nccn-inclusion-on-clinical-practice2026-07-01T12:05:00Z2026-07-01T12:05:00Z https://www.onclive.com/view/communicating-with-patients-and-families-about-investigational-ezh2-inhibition2026-07-01T12:05:00Z2026-07-01T12:05:00Z https://www.onclive.com/view/case-2-germline-brca2-kras-g12v-and-sequencing-strategies-in-a-young-fit-patient2026-07-01T12:00:00Z2026-07-01T12:00:00Z https://www.onclive.com/view/completing-the-molecular-workup-mutations-prame-and-the-case-for-early-hla-testing2026-07-01T12:00:00Z2026-07-01T12:00:00Z https://www.onclive.com/view/clinical-scenario-young-patient-with-idh-mutant-astrocytoma2026-07-01T12:00:00Z2026-07-01T12:00:00Z https://www.onclive.com/view/dr-harrison-on-implications-of-the-independence-data-for-luspatercept-in-myelofibrosis-associated-anemia2026-07-01T12:00:00Z2026-07-01T12:00:00Z https://www.onclive.com/view/treatment-selection-between-flaura2-and-mariposa2026-07-01T12:00:00Z2026-07-01T12:00:00Z https://www.onclive.com/view/strategic-positioning-of-ezh2-inhibition-with-enzalutamide-in-the-treatment-landscape2026-07-01T12:00:00Z2026-07-01T12:00:00Z https://www.onclive.com/view/fda-approval-insights-t-dxd-for-early-stage-her2-breast-cancer-with-charles-e-geyer-md2026-07-01T01:55:00Z2026-07-01T01:55:00Z https://www.onclive.com/view/dr-geyer-on-the-fda-approval-of-t-dxd-followed-by-thp-for-her2-breast-cancer2026-06-30T22:35:00Z2026-06-30T22:35:00Z https://www.onclive.com/view/dr-geyer-on-the-fda-approval-of-post-neoadjuvant-t-dxd-for-her2-breast-cancer2026-06-30T22:25:00Z2026-06-30T22:25:00Z https://www.onclive.com/view/glp-1-receptor-agonists-endocrine-therapy-and-metabolic-health-comprise-holistic-breast-cancer-care2026-06-30T21:58:31.419Z2026-06-30T21:58:31.419Z https://www.onclive.com/view/fda-approves-orca-t-for-matched-donor-hsct-in-hematologic-malignancies2026-06-30T21:56:40.596Z2026-06-30T21:56:40.596Z https://www.onclive.com/view/dr-vachhani-on-phase-2-efficacy-safety-data-for-sapablursen-in-polycythemia-vera2026-06-30T21:40:18.928Z2026-06-30T21:40:18.928Z https://www.onclive.com/view/dissecting-independence-data-and-the-role-of-luspatercept-in-myelofibrosis-associated-anemia-with-claire-harrison-md2026-06-30T21:11:56.374Z2026-06-30T21:11:56.374Z https://www.onclive.com/view/frontline-treatment-selection-in-egfr-mutated-non-small-cell-lung-cancer-monotherapy-versus-combination-strategies2026-06-30T21:00:00Z2026-06-30T21:00:00Z https://www.onclive.com/view/cns-surveillance-standards-and-practice-gaps-in-egfr-mutated-nsclc2026-06-30T20:07:19.160Z2026-06-30T20:07:19.160Z https://www.onclive.com/view/dr-ailawadhi-on-the-investigation-of-cemsidomide-in-multiple-myeloma2026-06-30T20:06:14.810Z2026-06-30T20:06:14.810Z https://www.onclive.com/view/first-line-cns-efficacy-in-egfr-mutated-nsclc-flaura2-and-mariposa-data2026-06-30T20:06:11.946Z2026-06-30T20:06:11.946Z https://www.onclive.com/view/as-adc-options-expand-sequencing-and-toxicity-management-become-the-next-challenges-in-gynecologic-oncology2026-06-30T19:49:16.172Z2026-06-30T19:49:16.172Z https://www.onclive.com/view/serena-6-splits-the-breast-cancer-field-on-switching-therapy-before-radiographic-progression-with-sara-nunnery-md-msci-and-megan-kruse-md2026-06-30T19:45:00Z2026-06-30T19:45:00Z https://www.onclive.com/view/medical-crossfire-turning-therapeutic-innovation-into-practice-personalizing-care-in-multiple-myeloma2026-06-30T19:33:31.821Z2026-06-30T19:33:31.821Z https://www.onclive.com/view/intensive-chemotherapy-in-combination-with-quizartinib-versus-midostaurin-for-flt3-itd-mutated-acute-myeloid-leukemia-a-multicenter-cohort-study2026-06-30T19:22:43.184Z2026-06-30T19:22:43.184Z https://www.onclive.com/view/zanubrutinib-vs-ibrutinib-in-tb-cll-implications-for-interpreting-fixed-duration-treatment-outcomes-from-cll172026-06-30T18:33:15.106Z2026-06-30T18:33:15.106Z https://www.onclive.com/view/foundations-of-metastatic-tnbc-biology-prognosis-and-the-treatment-paradigm2026-06-30T18:15:00.000Z2026-06-30T18:15:00Z https://www.onclive.com/view/mangrove-trial-shows-improved-efficacy-with-zanubrutinib-plus-rituximab-vs-chemo-in-mcl2026-06-30T17:45:00Z2026-06-30T17:45:00Z https://www.onclive.com/view/treatment-intensification-in-vulnerable-populations-arpi-use-in-elderly-frail-and-high-comorbidity-patients-with-mcspc-with-martin-schoen-md-and-andrew-w-hahn-md2026-06-30T17:00:00Z2026-06-30T17:00:00Z https://www.onclive.com/view/10-experts-predict-future-ctcl-treatment2026-06-30T16:42:57.722Z2026-06-30T16:42:57.722Z https://www.onclive.com/view/mayo-clinic-researchers-uncover-critical-link-in-the-immune-response-to-cancer2026-06-30T16:12:10.304Z2026-06-30T16:12:10.304Z https://www.onclive.com/view/experts-outline-the-evolving-role-of-ctdna-based-mrd-testing-across-solid-tumors2026-06-30T15:28:21.783Z2026-06-30T15:28:21.783Z https://www.onclive.com/view/multidisciplinary-communication-and-fda-approval-pathway-fundamentals2026-06-30T15:05:00.000Z2026-06-30T15:05:00Z https://www.onclive.com/view/evolution-of-radioligand-therapy-in-nets2026-06-30T15:00:00.000Z2026-06-30T15:00:00Z